While a higher percentage of patients in EU5 (68%) received treatment compared with patients in the United States (53%) and Japan (43%), probably reflecting disease severity at (later!) diagnosis, use of ATS guideline-compliant 3-drug macrolide regimens is limited in all regions, but particularly limited in the continental European countries. Read the full ERS 2014 poster here.
Monday, 15 September 2014 07:17
Treatment adherence
A NTM-NET chart review of patients treated for MAC disease in the US, Japan and 5 European countries showed that the percentage of patients who received treatment with the recommended 3-drug macrolide regimen for >6 months differed strongly by country.
Published in
NTM-NET NEWS